Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atumelnant in Classic Congenital Adrenal Hyperplasia (Calm-CAH)
NCT07144163Phase 3Recruiting
- Sponsor
- Crinetics Pharmaceuticals
- Start
- Dec 2025
- Primary completion
- May 2027
- Modality
- Allosteric Modulators, Orthosteric Ligands, Irreversible Covalent Inhibitors
- Countries
- 15
01
Overview
Phase 3, randomised, double-blind trial in classic congenital adrenal hyperplasia comparing Atumelnant with Placebo (2 arms). Primary endpoint: Proportion of participants with morning post-GC Androstenedione (A4) <= Upper Limit of Normal (ULN) who are on physiologic GC replacement at 32 weeks. Started Dec 2025; status: recruiting.
02
Drugs
atumelnant
03
Conditions
classic congenital adrenal hyperplasia
Beyond the preview
Go deeper on NCT07144163.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07144163.